https://www.fresenius.com en-us Tue, 09 Sep 2025 01:30:00 +0200 Tue, 09 Sep 2025 01:30:00 +0200 Tue, 09 Sep 2025 01:30:00 +0200 <![CDATA[Fresenius successfully places bonds with a volume of 1 billion euros]]> Mon, 08 Sep 2025 21:00:00 +0200 <![CDATA[Fresenius receives a €400 million EIB loan to support R&D, innovation and capacity expansion across the EU]]> Mon, 01 Sep 2025 16:00:00 +0200 <![CDATA[Fresenius continues streamlining its operations with the divestment of the Calea homecare business in Canada]]> Tue, 26 Aug 2025 16:14:38 +0200 <![CDATA[Fresenius leads new EASYGEN consortium aimed at decentralizing CAR-T cell therapy and improving hospital workflows]]> here.]]> Wed, 06 Aug 2025 12:45:00 +0200 <![CDATA[Fresenius Q2/25: Guidance raised - Resilient business continues to deliver consistent performance]]> Tue, 05 Aug 2025 15:42:21 +0200 <![CDATA[Fresenius announces licensing agreement with Polpharma Biologics to commercialize a proposed vedolizumab biosimilar candidate]]> Wed, 23 Jul 2025 17:15:00 +0200 <![CDATA[Fresenius Receives European Commission Approval for Denosumab Biosimilars]]> Wed, 16 Jul 2025 21:00:00 +0200 <![CDATA[Fresenius publishes Aide Memoire for the upcoming Q2 2025 reporting]]> website. The results of the second quarter and first half of 2025 of Fresenius SE & Co. KGaA will be published on 6 August 2025. The Quiet Period will start on 24 July 2025. ]]> Thu, 03 Jul 2025 20:55:04 +0200 <![CDATA[Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability]]> here.]]> Tue, 27 May 2025 17:00:00 +0200 <![CDATA[Anke Schmidt appointed Head of Corporate Communications at Fresenius]]> Tue, 27 May 2025 15:30:00 +0200 <![CDATA[Denosumab CHMP Positive Opinion ]]> Tue, 20 May 2025 21:00:00 +0200 <![CDATA[Fresenius expands its line of Epinephrine injectables in the U.S. ]]> Wed, 07 May 2025 12:45:00 +0200 <![CDATA[Fresenius Q1/25: Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum]]> Thu, 10 Apr 2025 01:00:00 +0200 <![CDATA[Fresenius makes progress on streamlining its production network]]> Tue, 01 Apr 2025 17:00:00 +0200 <![CDATA[Fresenius completes divestment of Vamed’s international project business]]> Wed, 26 Mar 2025 23:00:00 +0100 <![CDATA[Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement ]]> here. Please click to see full Prescribing Information for Conexxence®. Please click to see full Prescribing Information for Bomyntra®. ]]> Wed, 26 Mar 2025 21:00:00 +0100 <![CDATA[Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient]]> European Sustainability Reporting Standards (ESRS). This replaces the Non-financial Report of previous Annual Reports and expands and supplements reporting topics and details. In addition, the ESRS report, like the financial report, is audited externally. The 2024 Annual Report is available in German and English as a PDF file and as an online version. Further publication and event dates for 2025: · 04/24/2025: Publication of Sustainability Highlights Magazine · 05/07/2025: Publication of the financial results for Q1 2025 · 05/23/2025: Annual General Meeting · 08/06/2025: Publication of the financial results for Q2 2025 · 11/05/2025: Publication of the financial results for Q3 2025 ]]> Tue, 04 Mar 2025 15:00:00 +0100 <![CDATA[Fresenius completes sale of shares in Fresenius Medical Care AG]]> Tue, 04 Mar 2025 01:45:38 +0100 <![CDATA[Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share]]> Mon, 03 Mar 2025 21:00:00 +0100 <![CDATA[Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar ]]>